The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Dual tissue and plasma testing to improve detection of actionable variants in patients with solid cancers.
 
Matthew Mackay
Employment - Tempus
Stock and Other Ownership Interests - Tempus
 
Nicholas Mitsiades
No Relationships to Disclose
 
Young Kwang Chae
Consulting or Advisory Role - AstraZeneca; Biodesix; Boehringer Ingelheim; Counsyl; Foundation Medicine; Guardant Health; Hanmi; Immuneoncia; Lilly; Lunit; Roche/Genentech; Takeda; Tempus
Speakers' Bureau - AstraZeneca; G1 Therapeutics; Genentech/Roche; Jazz Pharmaceuticals; Lilly; Merck
Research Funding - Abbvie; Biodesix; Bristol-Myers Squibb; Freenome; Lexent Bio
Travel, Accommodations, Expenses - Hanmi
 
Andrew A. Davis
No Relationships to Disclose
 
Philip Edward Lammers
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Merck; Pfizer; Puma Biotechnology; Tempus; Teva
 
James F. Maher
No Relationships to Disclose
 
Dan Theodorescu
No Relationships to Disclose
 
Peter Rubin
No Relationships to Disclose
 
Timothy J. Pluard
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Genentech; Gilead Sciences; H3 Biomedicine; Macrogenics; Novartis; Pfizer; Seagen
Speakers' Bureau - Genentech/Roche; Gilead Sciences; Novartis; Seagen
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); DAEHWA Pharmaceutical (Inst); Dantari (Inst); G1 Therapeutics (Inst); H3 Biomedicine (Inst); HiberCell (Inst); Olema Pharmaceuticals (Inst); Orinove (Inst); Orinove (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst); Zymeworks (Inst)
 
Lee Langer
Employment - Tempus
Stock and Other Ownership Interests - Tempus
Patents, Royalties, Other Intellectual Property - A pending patent for a method to determine pathway-level disruption from RNA. (Inst)
 
Kabir Manghnani
Employment - Tempus
 
Rotem Ben-Shachar
Employment - Myriad Genetics; Tempus
Stock and Other Ownership Interests - Myriad Genetics; Tempus
Travel, Accommodations, Expenses - Myriad Genetics
 
Kimberly L. Blackwell
Employment - Lilly; Tempus
Leadership - Century Therapeutics; cereius; Monte Rosa Therapeutics; zentalis
Stock and Other Ownership Interests - Lilly; Monte Rosa Therapeutics; zentalis
 
James Lin Chen
Consulting or Advisory Role - Syapse; Tempus
Speakers' Bureau - Foundation Medicine
Research Funding - Eisai
Patents, Royalties, Other Intellectual Property - MatchTX
 
Joel Dudley
Employment - Tempus
Leadership - Tempus
Stock and Other Ownership Interests - Tempus
Patents, Royalties, Other Intellectual Property - Personalis
 
Justin Guinney
Employment - Tempus
Consulting or Advisory Role - AstraZeneca
Research Funding - AstraZeneca (Inst); Bristol Meyers Squib (Inst); Roche/Genentech (Inst)
 
Wade Thomas Iams
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb/Pfizer; Chardan Consulting; Curio Science; Defined Health; G1 Therapeutics; Janssen; Jazz Pharmaceuticals; Mirati Therapeutics; Outcomes Insights; Takeda